Live
- Director Malli Ankam unveils insights into Allari Naresh’s ‘Aa Okkati Adakku’
- Crisis of Loyalty: Congress Leaders Defecting To BJP Sparks Concerns
- Anand Devarakonda’s ‘Gam Gam Ganesha’ set to hit theaters on May 31st
- IPL 2024: With belief in process, Ravi Bishnoi remains hopeful of selection in T20 WC
- Preity Zinta misses 'Pati Parmeshwar' Gene Goodenough, drops adorable video
- Jaipur International Airport receives another hoax bomb threat
- Ultratech posts 35 per cent jump in Q4 net profit, declares dividend of Rs 70 per share
- Seven dead in attack on Russian police post in the North Caucasus
- Sony PS5 Slim Gets a Price Drop in Summer Sale: Check Offers
- Bank Nifty at record high levels
Glenmark gets nod for Deferasirox tablets
Glenmark Pharmaceuticals on Tuesday said it has got final approval from the US health regulator for Deferasirox tablets for oral suspension.
New Delhi: Glenmark Pharmaceuticals on Tuesday said it has got final approval from the US health regulator for Deferasirox tablets for oral suspension.
"Glenmark Pharmaceuticals Inc, USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (US FDA) for Deferasirox tablets for oral suspension, 125 mg, 250 mg and 500 mg, the generic version of exjade1 tablets for oral suspension, 125 mg, 250 mg and 500 mg, of Novartis Pharmaceuticals Corporation," the company said in a filing to the BSE.
The tablet is used to treat high levels of iron in the body caused by multiple blood transfusions.
According to IQVIA sales data for the 12-month period ending November 2019, exjade tablets for oral suspension -- 125 mg, 250 mg and 500 mg -- had annual sales of approximately $106.4 million (about Rs 750 crore).
Glenmark's current portfolio consists of 165 products authorised for distribution in the US market and 43 ANDAs pending approval with the US FDA.
In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.
